Success Story: Dual Immigration Victory! Senior Lecturer Secures NIW & EB1A Approvals with Premium Processing – Even with EB1A RFE

Client’s Testimonial:

“Your services are excellent. I am thrilled to learn about the successful outcome of your hard work and commitment to my case. I greatly appreciate the efforts of your firm. Thank you so much for everything.”

On February 14^th, 2024, and February 27^th, 2025, we received another I-140 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) Approvals for a Senior Lecturer (Approval Notice).

General Field: Public Health

Position at the Time of Case Filing: Senior Lecturer

Approval Notice Date: : February 14^th, 2024 (NIW); February 27^th, 2025 (EB1A)

Processing Time: 13 days (NIW), and 2 months, 25 days (EB1A) (Premium Processing Requested)

Case Summary:

We’re pleased to share the approval of both the I-140 National Interest Waiver (NIW) and EB1A immigrant petitions for a highly accomplished public health expert specializing in infectious diseases, global health, and biostatistics.

With an M.B.B.S. degree and deep expertise in epidemiological research, the petitioner has made significant contributions to understanding health behaviors and vaccine uptake, particularly in underserved populations. Her work is particularly notable for investigating immunization knowledge, attitudes, and behaviors in Nigeria – a topic with wide-reaching implications for public health systems globally.

Currently engaged in academic and research roles, the petitioner’s work bridges scientific evidence and population-level health interventions. She has published 35 peer-reviewed journal articles, including 8 as first author, and 1 abstract. Collectively, her research has been cited 356 times, reflecting her influence across the global health research community. Her findings have shaped discussions on public health interventions, particularly within the context of improving immunization and disease prevention strategies in low- and middle-income countries.

The petitioner’s expertise has also been recognized through her active involvement in scholarly peer review, having completed at least 16 reviews for respected public health journals. This level of engagement reflects her stature in the field and the trust that editors place in her scientific judgment.

Her achievements were further supported by four strong recommendation letters, which were submitted with the EB1A petition. These letters came from both independent and affiliated experts who praised her leadership in the field of infectious disease epidemiology and highlighted her work as essential to improving global public health outcomes.

“Ensuring the continuation of the petitioner’s work is thus deeply important to both public health research and to the nation, and his work must be allowed to continue.”

In addition to presenting strong publication and citation metrics, we established the petitioner’s significance through a clear demonstration of how her work addresses pressing national and international health challenges. Her research aligns closely with U.S. public health goals, particularly those related to disease prevention, immunization equity, and data-driven policy interventions.

After receiving a request for evidence (RFE) in the EB1A process, we presented a carefully constructed legal response that clearly articulated the national and international impact of her work. The result was a successful approval of both petitions.

We congratulate this exceptional physician-researcher and look forward to her continued impact in strengthening public health systems worldwide.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.